Activated charcoal to prevent irinotecan-induced diarrhea in children

Pediatric Blood and Cancer

Volumn 51, Issue 1, 2008, Pages 49-52

  Sergio, Gallegos Castorena ^a   Félix, Gaytán Morales ^b   Luis, Juárez Villegas ^b  

^a HOSPITAL CIVIL DE GUADALAJARA FRAY ANTONIO ALCALDE   (Mexico)

^b HOSPITAL INFANTIL DE MÉXICO FEDERICO GÓMEZ   (Mexico)

Author keywords

Chemotherapy; Clinical trials; Supportive care

Indexed keywords

ACTIVATED CARBON; CARBOPLATIN; CISPLATIN; DOXORUBICIN; IRINOTECAN; LOPERAMIDE;

ADOLESCENT; ARTICLE; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; DESCRIPTIVE RESEARCH; DIARRHEA; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; FISHER EXACT TEST; GASTROINTESTINAL TOXICITY; HUMAN; MALABSORPTION; MALE; MULTIPLE CYCLE TREATMENT; OPEN STUDY; PATIENT COMPLIANCE; PRESCHOOL CHILD; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANK SUM TEST; SCHOOL CHILD; SOLID TUMOR;

ADOLESCENT; ANTINEOPLASTIC AGENTS; CAMPTOTHECIN; CHARCOAL; CHILD; CHILD, PRESCHOOL; DIARRHEA; FEMALE; HUMANS; INFANT; MALE; NEOPLASMS; TREATMENT OUTCOME;

EID: 44149123400     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.21491     Document Type: Article

References (29)

1. Vassal G, Doz F, Frappaz D, et al. A phase I study of irinotecan as a 3-week schedule in children with refractory or recurrent solid tumors. J Clin Oncol 2003;21:3844-3852.
2. Saliba F, Hagipantelli R, Misset JL, et al. Pathophysiology and therapy of irinotecan-induced delayed-onset diarrhea in patients with advanced colorectal cancer: A prospective assessment. J Clin Oncol 1998;16:2745-2751.
3. Saltz LB, Cox JV, Blanke C, et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. N Engl J Med 2000;343:905-914.
4. Douillard JY, Cunningham D, Roth AD, et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: A multicentre randomised trial. Lancet 2000;355:1041-1047.
5. Takasuna K, Hagiwara T, Hirohashi M, et al. Involvement of beta-glucuronidase in intestinal microflora in the intestinal toxicity of the antitumor camptothecin derivative irinotecan hydrochloride (CPT-11) in rats. Cancer Res 1996;56:3752-3757.
6. Ikuno N, Soda H, Watanabe M, et al. Irinotecan and characteristic mucosal changes in the mouse ileum and cecum. J Natl Cancer Inst 1995;87:1876-1883.
7. Saliba F, Hagipantelli R, Misset JL, et al. Pathophysiology and therapy of irinotecan-induced delayed-onset diarrhea in patients with advanced colorectal cancer: A prospective assessment. J Clin Oncol 1998;16:2745-2751.
8. Xie R, Mathijssen RH, Sparreboom A, et al. Clinical pharmacokinetics of irinotecan and its metabolites in relation with diarrhea. Clin Pharmacol Ther 2002;72:265-275.
9. Xie R, Mathijssen RH, Sparrebom A, et al. Clinical pharmacokinetics of irinotecan and its metabolites: A population analysis. J Clin Oncol 2002;20:3293-3301.
10. Rothenberg ML, Meropol NJ, Poplin EA, et al. Mortality associated with irinotecan plus bolus fluorouracil/leucovorin: Summary findings of an independent panel. J Clin Oncol 2001;19:3801-3807.
11. Benson AB III, Ajani JA, Catalano RB, et al. Recommendad guidelines for the treatment of cancer treatment-induced diarrhea. J Clin Oncol 2004;22:2918-2926.
12. Rubin J, Ajani J, Schirmer W, et al. Octreotide acetate long acting formulation versus open-label subcutaneos octreotide acetate in malignant carcinoid syndrome. J Clin Oncol 1999;17:600-606.
13. Beglinger C, Drewer J. Somatostatin and octreotide: Physiological background and pharmacological application. Digestion 1999;60:2-8.
14. Alimonti A, Gelibter A, Pavese I, et al. New approaches to prevent intestinal toxicity of irinotecan-based regimens. Cancer Treat Rev 2004;30:555-562.
15. Michael M, Brittain MA, Nagai J, et al. Phase II study of activated charcoal to prevent irinotecan-induced diarrhea. J Clin Oncol 2004;22:4410-4417.
16. Ikegami T, Ha L, Arimori K, et al. Intestinal alkalization as a possible preventive mechanism in irinotecan (CPT-11)-induced diarrhea. Cancer Res 2002;62:179-187.
17. Valentí Moreno V, Brunet Vidal J, Manzano Alemany H, et al. Prevention of irinotecan associated diarrhea by intestinal alkalization. A pilot study in gastrointestinal cancer patients. Clin Transl Oncol 2006;8:208-212.
18. Hamada A, Aoki A, Terazaki H, et al. Pharmacokinetic changes of irinotecan by intestinal alkalinization in advanced colorectal cancer patients. Ther Drug Monit 2005;27:536-538.
19. Kehrer DFS, Sparreboom A, Verweij J, et al. Modulation of irinotecan-induced diarrhea by co-treatment with neomycin in cancer patients. Clin Cancer Res 2001;7:1136-1141.
20. de Jong FA, Kehrer DFS, Mathijssen RHJ, et al. Prophylaxis of irinotecan-induced diarrhea with neomycin and potential role for UGT1A1*28 genotype screening: A double-blind, randomized, placebo-controlled study. Oncologist 2006;11:944-954.
21. Furman WL, Crews KR, Billups C, et al. Cefixime allows greater dose escalation of oral irinotecan: A phase I study in pediatric patients with refractory solid tumors. J Clin Oncol 2005;24:563-570.
22. Furman WL, Clinton FS, Poquette CA, et al. Direct translation of a protracted irinotecan schedule from a xenograft model to a phase I trial in children. J Clin Oncol 1999;18:1815-1824.
23. Wagner LM, Crews KR, Iacono LC, et al. Phase I trial of temozolamide and protracted irinotecan in pediatric patients with solid refractory tumors. Clin Cancer Res 2004;10:840-848.
24. Whörer SS, Raderer M, Hejna M. Palliative chemotherapy for advanced gastric cancer. Ann Oncol 2004;15:1585-1595.
25. Balram C, Zhou QY, Cheung YB, et al. Influence of multiple dose activated charcoal on the disposition kinetics of irinotecan in rats. Drug Metabol Drug Interact 2002;19:137-148.
26. Mori K, Kondo T, Kamiyama Y, et al. Preventive effect of Kampo medicine (Hangeshashin-to) against irinotecan induced diarrhea in advanced in advanced non-small-cell lung cancer. Cancer Chemother Pharmacol 2003;51:403-406.
27. Chowbay B, Sharma A, Zhou QY, et al. The modulation of irinotecan-induced diarrhea and pharmacokinetics by three different classes of pharmacologic agents. Oncol Rep 2003;10:745-751.
28. Maeda Y, Ohune T, Nakamura M, et al. Prevention of irinotecan-induced diarrhoea by oral carbonaceous adsorbent (Kremezin) in cancer patients. Oncol Rep 2004;12:581-585.
29. Hidaka M, Yamasaki K, Okumura M, et al. Adsorption of irinotecan onto oral adsorbent AST 120(Kremezin) for preventing delayed diarrhea. Cancer Chemother Pharmacol 2007;59:321-328.